{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:11:21Z","timestamp":1770351081461,"version":"3.49.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>There have been few clinically useful targetable biomarkers in uterine cervical carcinomas. Estrogen receptor (ER), HER2, and fibroblast activation protein (FAP) are potential therapeutic or theranostic targets in other gynecologic and genitourinary carcinoma types. We determined the immunohistochemical expression patterns of these markers in treatment-naive cervical carcinoma, and whether expression correlated with clinical outcomes after definitive chemoradiation therapy. Tissue microarrays were created from 71 patient samples taken before therapy (57 squamous cell carcinomas and 14 nonsquamous cell carcinomas) and stained for ER, HER2, and FAP. ER was positive in 25\/70 cases (36%). Of 66 tumors with evaluable HER2 staining, only 1 had positive (3+) staining (3%, positive for HER2 amplification by fluorescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization), and 1 had equivocal (2+) staining (negative for amplification by fluorescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization). The remainder were negative for HER2 overexpression. FAP expression was widely variably in the tumor stroma. ER positivity and FAP expression did not correlate with cervical recurrence, pelvic recurrence, distant recurrence, or cancer death. In conclusion, HER2 amplification is very rare in nonmetastatic treatment-naive cervical carcinomas, but if present, could represent a target for antibody therapy. ER and FAP were expressed in a subset of tumors, but expression did not correlate with clinical outcomes. These immunohistochemical markers do not demonstrate prognostic significance in treatment-naive cervical cancer, but they may have utility in targeted therapy or imaging.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000853","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T22:05:31Z","timestamp":1642975531000},"page":"628-635","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas"],"prefix":"10.1097","volume":"41","author":[{"given":"Lulu","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly C.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry W.","family":"Grigsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Markovina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Due\u00f1as-Gonz\u00e1lez","year":"2011","journal-title":"J Clin Oncol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3802\/jgo.2019.30.e82","article-title":"A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial","volume":"30","author":"Tangjitgamol","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Vale","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R5-20250802","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA3","article-title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)","volume":"39","author":"Mileshkin","year":"2021","journal-title":"J Clin Oncol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2019.00065","article-title":"PD-1\/PD-L1 inhibitors in cervical cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2217\/fon.14.110","article-title":"Estrogen and progesterone receptors in breast cancer","volume":"10","author":"Yip","year":"2014","journal-title":"Futur Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.humpath.2013.06.016","article-title":"Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer","volume":"44","author":"Tchou","year":"2013","journal-title":"Hum Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO;2-U","article-title":"Stromal expression of fibroblast activation protein\/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast","volume":"95","author":"Ariga","year":"2001","journal-title":"Int J Cancer"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12307-014-0153-7","article-title":"Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer","volume":"8","author":"Mhawech-Fauceglia","year":"2015","journal-title":"Cancer Microenviron"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-55013-0","article-title":"Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome","volume":"10","author":"Mezheyeuski","year":"2020","journal-title":"Sci Rep"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-\u03b1","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjc.2017.390","article-title":"Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer","volume":"118","author":"Markovina","year":"2018","journal-title":"Br J Cancer"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-20-4450","article-title":"Standardized uptake value for 18 F-fluorodeoxyglucose is a marker of inflammatory state and immune infiltrate in cervical cancer","volume":"27","author":"Floberg","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JOP.18.00206","article-title":"HER2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update summary","volume":"14","author":"Wolff","year":"2018","journal-title":"J Oncol Pract"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2741\/4682","article-title":"Targeting fibroblast activation protein in cancer\u2014prospects and caveats","volume":"23","author":"Busek","year":"2018","journal-title":"Front Biosci Landmark"},{"key":"R20-20250802","first-page":"153","article-title":"Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas","volume":"26","author":"Kwasniewska","year":"2011","journal-title":"Oncol Rep"},{"key":"R21-20250802","first-page":"1341","article-title":"Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters","volume":"30","author":"Bodner","year":"2010","journal-title":"Anticancer Res"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"E3255","DOI":"10.1073\/pnas.1509322112","article-title":"Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling","volume":"112","author":"Den Boon","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<505::AID-CNCR12>3.0.CO;2-7","article-title":"Adenocarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors","volume":"79","author":"Fujiwara","year":"1997","journal-title":"Cancer"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/PGP.0000000000000102","article-title":"Differential patterns of PAX8, p16,and ER immunostains in mesonephric lesions and adenocarcinomas of the cervix","volume":"33","author":"Goyal","year":"2014","journal-title":"Int J Gynecol Pathol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0090-8258(92)90131-2","article-title":"Estrogen and progesterone receptor assay in carcinoma of the cervix with monoclonal antibodies","volume":"47","author":"Kim","year":"1992","journal-title":"Gynecol Oncol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/1097-0142(19901215)66:12<2620::AID-CNCR2820661226>3.0.CO;2-S","article-title":"Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix","volume":"66","author":"Nonogaki","year":"1990","journal-title":"Cancer"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2298\/MPNS1408202N","article-title":"An immunohistochemical analysis of sex-steroid receptors, tumor suppressor gene p53 and Ki-67 in the normal and neoplastic uterine cervix squamous epithelium","volume":"67","author":"Nikolaou","year":"2014","journal-title":"Med Pregl"},{"key":"R28-20250802","first-page":"376","article-title":"Down regulation of estrogen receptor expression is an early event in human papillomavirus infected cervical dysplasia","volume":"26","author":"Bekkers","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/ijc.21953","article-title":"Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies","volume":"119","author":"Rajkumar","year":"2006","journal-title":"Int J Cancer"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies","volume":"370","author":"Appleby","year":"2007","journal-title":"Lancet"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1073\/pnas.0409883102","article-title":"Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model","volume":"102","author":"Brake","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"29361","DOI":"10.18632\/oncotarget.12957","article-title":"Antiestrogen use reduces risk of cervical neoplasia in breast cancer patients: a population-based study","volume":"8","author":"Hsieh","year":"2017","journal-title":"Oncotarget"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"19467","DOI":"10.1073\/pnas.0911436106","article-title":"Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists","volume":"106","author":"Chung","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ajpath.2013.10.013","article-title":"Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy","volume":"184","author":"Spurgeon","year":"2014","journal-title":"Am J Pathol"},{"key":"R35-20250802","first-page":"3335","article-title":"SERMs suppresses the growth of ER\u03b1 positive cervical cancer xenografts through predominant inhibition of extra-nuclear ER\u03b1 expression","volume":"11","author":"Ramachandran","year":"2021","journal-title":"Am J Cancer Res"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"36219","DOI":"10.18632\/oncotarget.5283","article-title":"HER2 as a novel therapeutic target for cervical cancer","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.pgp.0000092137.88121.8d","article-title":"Overexpression\/amplification of HER-2\/neu is uncommon in invasive carcinoma of the uterine cervix","volume":"23","author":"Rosty","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.pgp.0000139670.49581.b3","article-title":"HER2 protein (p185HER2) is only rarely overexpressed in cervical cancer","volume":"23","author":"Fadare","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00795-018-0202-2","article-title":"Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification","volume":"52","author":"Nakamura","year":"2018","journal-title":"Med Mol Morphol"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification","volume":"7","author":"Shi","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fonc.2019.00560","article-title":"Radiopharmaceuticals for persistent or recurrent uterine cervix cancer","volume":"9","author":"Kunos","year":"2019","journal-title":"Front Oncol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"100520","DOI":"10.1016\/j.gore.2019.100520","article-title":"HER2-positive metastatic cervical cancer responsive to first and second-line treatment: a case report","volume":"31","author":"Fortman","year":"2020","journal-title":"Gynecol Oncol Reports"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:43Z","timestamp":1754161423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000853","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}